233 related articles for article (PubMed ID: 33032292)
1. The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
Wei CC; Hsiao YP; Gau SY; Wu YT; Wu CT; Wu MH; Tsai JD
Dermatology; 2021; 237(3):444-449. PubMed ID: 33032292
[TBL] [Abstract][Full Text] [Related]
2. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC
Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
[TBL] [Abstract][Full Text] [Related]
4. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies.
Franz DN; Budde K; Kingswood JC; Belousova E; Sparagana S; de Vries PJ; Berkowitz N; Ridolfi A; Bissler JJ
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1796-1803. PubMed ID: 29569806
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of everolimus on small renal angiomyolipoma in cases of tuberous sclerosis complex-related epilepsy and subependymal giant cell astrocytoma.
Hatano T; Yuri Y
Asian J Surg; 2023 Mar; 46(3):1236-1237. PubMed ID: 36031512
[No Abstract] [Full Text] [Related]
6. Rapamycin and rapalogs for tuberous sclerosis complex.
Sasongko TH; Ismail NF; Zabidi-Hussin Z
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011272. PubMed ID: 27409709
[TBL] [Abstract][Full Text] [Related]
7. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
Krueger DA; Care MM; Holland K; Agricola K; Tudor C; Mangeshkar P; Wilson KA; Byars A; Sahmoud T; Franz DN
N Engl J Med; 2010 Nov; 363(19):1801-11. PubMed ID: 21047224
[TBL] [Abstract][Full Text] [Related]
8. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN
Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041
[TBL] [Abstract][Full Text] [Related]
9. Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma.
Song X; Said Q; Tran O; Krueger DA; Bissler J
Curr Med Res Opin; 2019 Jun; 35(6):1103-1110. PubMed ID: 30550347
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.
Lee YI; Lee JH; Kim DY; Chung KY; Shin JU
Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060
[TBL] [Abstract][Full Text] [Related]
12. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.
Bissler JJ; Budde K; Sauter M; Franz DN; Zonnenberg BA; Frost MD; Belousova E; Berkowitz N; Ridolfi A; Christopher Kingswood J
Nephrol Dial Transplant; 2019 Jun; 34(6):1000-1008. PubMed ID: 30053159
[TBL] [Abstract][Full Text] [Related]
13. Effects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: A preliminary report.
Tsai JD; Wei CC; Yang SH; Fan HC; Hsu CC; Tung MC; Tsai ML; Sheu JN
Nephrology (Carlton); 2017 Dec; 22(12):1017-1022. PubMed ID: 27565896
[TBL] [Abstract][Full Text] [Related]
14. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y
Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice.
Cockerell I; Christensen J; Hoei-Hansen CE; Holst L; Grenaa Frederiksen M; Issa-Epe AI; Nedregaard B; Solhoff R; Heimdal K; Johannessen Landmark C; Lund C; Nærland T
Orphanet J Rare Dis; 2023 Dec; 18(1):377. PubMed ID: 38042867
[TBL] [Abstract][Full Text] [Related]
16. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
[TBL] [Abstract][Full Text] [Related]
18. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Belousova E; Frost MD; Sauter M; Brakemeier S; de Vries PJ; Berkowitz N; Voi M; Peyrard S; Budde K
PLoS One; 2017; 12(8):e0180939. PubMed ID: 28792952
[TBL] [Abstract][Full Text] [Related]
19. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.
Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I
Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960
[TBL] [Abstract][Full Text] [Related]
20. The combination of photodynamic therapy and ultrapulse carbon dioxide laser for facial angiofibromas in tuberous sclerosis complex: A case report.
Wang B; Yao Y; Huang X; Zhang L; Peng D; Zhang G
Photodiagnosis Photodyn Ther; 2022 Mar; 37():102725. PubMed ID: 35041984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]